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Background: Pressure ulcers are considered an important issue, mainly affecting immobilized older patients. These
pressure ulcers increase the care burden for the professional health service staff as well as pharmaceutical
expenditure. There are a number of studies on the effectiveness of different products used for the prevention of
pressure ulcers; however, most of these studies were carried out at a hospital level, basically using hyperoxygenated
fatty acids (HOFA). There are no studies focused specifically on the use of olive-oil-based products and therefore
this research is intended to find the most cost-effective treatment and achieve an alternative treatment.
Methods/design: The main objective is to assess the effectiveness of olive oil, comparing it with HOFA, to treat
immobilized patients at home who are at risk of pressure ulcers. As a secondary objective, the cost-effectiveness
balance of this new application with regard to the HOFA will be assessed. The study is designed as a noninferiority,
triple-blinded, parallel, multi-center, randomized clinical trial. The scope of the study is the population attending
primary health centers in Andalucía (Spain) in the regional areas of Malaga, Granada, Seville, and Cadiz. Immobilized
patients at risk of pressure ulcers will be targeted. The target group will be treated by application of an olive-oil-based
formula whereas the control group will be treated by application of HOFA to the control group. The follow-up period
will be 16 weeks. The main variable will be the presence of pressure ulcers in the patient. Secondary variables include
sociodemographic and clinical information, caregiver information, and whether technical support exists. Statistical
analysis will include the Kolmogorov-Smirnov test, symmetry and kurtosis analysis, bivariate analysis using the Student’s
t and chi-squared tests as well as the Wilcoxon and the Man-Whitney U tests, ANOVA and multivariate logistic
regression analysis.
Discussion: The regular use of olive-oil-based formulas should be effective in preventing pressure ulcers in
immobilized patients, thus leading to a more cost-effective product and an alternative treatment.
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Pressure ulcers are considered to be an economic, social
and health problem that does not just decrease the quality
of life of the patients and their social and familiar environ-
ment but also involves the worsening of the patients’
prognosis, as well as decreasing the patients’ life expect-
ancy, owing to the high number of related physical com-
plications. Pressure ulcers may be defined as injuries to
the skin caused by the ischaemic process that may affect
and necrotize those areas in the epidermis, dermis, sub-
cutaneous tissues, and muscles where the pressure ulcers
appear, and may also affect bones and joints in the most
severe cases. Pressure ulcers tend to appear when the soft
tissues are compressed between two layers, namely, the
bony prominences of the patient and an external surface
[1]. Additionally contributing to their appearance are the
vascular occlusion produced by the external pressure and
the endothelial damage to arterioles and microcirculation,
mainly due to tangential shear and frictional forces. Pres-
sure ulcers involve the alteration of a basic need for pa-
tients, which is to preserve skin integrity. Pressure ulcers
may appear in any part of the body, with the bony promi-
nences (sacrum, hips, heels) being most common, and
mainly affect older people, immobilized patients with severe
acute disease and patients with neurological deficiencies.
The incidence and prevalence of pressure ulcers are some
of the most representative indicators of the quality of nurs-
ing care. The data on pressure ulcer prevalence in Spanish
hospitals (8.24%) [2] are very similar to its neighboring
countries, Italy (8.3%), France (8.9%), Germany (10.2%), and
Portugal (12.5%) [3,4] or countries further afield, such as
Jordan (12%) [5]. The highest records of prevalence are
registered in Ireland (18.5%), Wales (26.7%) [6], Belgium
(21.1%), the United Kingdom (21.9%), Denmark (22.7%),
and Sweden (23.0%) [7]. The appearance of pressure ul-
cers in hospitalized patients is a frequent complication,
which has a negative impact on the patient’s health and
often causes an extension of the hospitalization period
and, thus, an increase in healthcare expenses.
With regard to nursing care at home, there are no spe-
cific records that compare the prevalence in patients in-
cluded in programs of nursing care at home given that
the characteristics of the health systems vary consider-
ably from one country to another. In nursing homes, the
most important study carried out might be the one re-
cently published by Park-Lee [8], which analyzes a sam-
ple of American nursing homes for older people and
reports a pressure ulcer prevalence of (11%), similar to
the Spanish rate.
With regard to primary healthcare, there are no spe-
cific data concerning patients who receive nursing care
at home with which to make a comparison on the preva-
lence of pressure ulcers in Spain with different countries,
given that the characteristics of the health systems varysubstantially from one country to another. According to
data obtained from the second National Study on Pres-
sure Ulcers Prevalence in Spain, in 2005 [9], the crude
prevalence pressure ulcers was registered at 3.73% and
the mean prevalence rate was registered at 9.11% ±
10.9% for those patients over 14 years who are included
in the nursing care at home service. The most common
ulcer sites are the sacrum and heels, affecting mainly the
population group, including people over 65 years. The
Third National Study on Pressure Ulcers Prevalence in
Spain shows that in 2009 [2] the crude prevalence was
5.89%. This rising percentage is due to the Spanish popula-
tion aging, since this study was carried in 2005 up to 2009.
Today, pressure ulcers are considered an important
health problem involving a financial impact, which sub-
stantially increases pharmaceutical expenditure. The total
spending derived from the treatment of pressure ulcers
represents 5% of the annual healthcare spending [10], and
generates a heavier health care workload for the profes-
sional staff.
The main risk factors causing pressure ulcers are immo-
bility, incontinence, malnutrition, and awareness level.
Pressure ulcers are an indirect indicator of health care
quality, thus a low prevalence of pressure ulcers in pa-
tients suggests a higher quality in the health care services,
based on the use of preventative measures. The assess-
ment of risk factors, the use of support surfaces, the repo-
sitioning of the patient, a good nutritional status, and skin
moisturizing or the use of checklists are adequate strat-
egies to prevent pressure ulcers [11-18] that have been
proved effective even in older patients [19].
A number of products are intended for the prevention of
pressure ulcers, such as oil compounds based on hyper-
oxygenated fatty acids (HOFA). A large number of studies
have proven their effectiveness in avoiding pressure ulcers
or by postponing the appearance of such pressure ulcers by
maintaining skin integrity [20-25]. However, one inconveni-
ence of this treatment is its high cost in the long term.
In Mediterranean cultures, olive oil is an essential elem-
ent with proven effects as a basic component of the diet
in the prevention of cardiovascular disease. However, to-
gether with its nutritional properties, it also provides bene-
ficial effects when applied topically, mainly owing to its
moisturizing and emollient qualities, and its composition
has led to its use as an ointment. Olive oil is composed of
98% triglycerides, including predominantly monounsatu-
rated oleic acids, which owing to their antiinflammatory
properties have been proven to be essential for health and
skin maintenance, as such properties are similar to ibupro-
fen (recent studies attribute this to Oleocanthal), and this
may accelerate the recovery and healing process of wounds
[26]. Furthermore, owing to the high concentration of
polyphenols, which are natural antioxidants, included in
extra virgin olive oil, its use mitigates the inflammatory
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flammatory disorders [27,28]. The role of oleic acid is a
key feature within the reconstruction of cell membranes,
providing higher smoothness to the dermis by restoring
skin humidity levels, thus moisturizing the skin and pro-
viding it with elasticity. Besides, such oil components as
phenolic compounds and chlorophyll have a high antioxi-
dant effect and are therefore anti-aging, apart from accel-
erating the dermis healing process. Moreover, it should
also be mentioned that vitamin E is included in the oil
composition, which is an excellent source of protection
against the free radicals causing cell oxidation [29]. An ex-
cess of free radicals in the organism accelerates aging and
as a result, epithelial cell membranes are modified, thus
making skin nutrition difficult, and also damaging the col-
lagen and elastin fibres, so that the skin loses its firmness
and elasticity. These free radicals include a 7-electron oxy-
gen atom: the stable oxygen atom has eight electrons and
becomes unstable when it loses one electron. When such
an electron is missing, it is borrowed from the cell mem-
brane and produces another free radical, causing a chain
reaction. This is counteracted by the action of antioxidants,
which neutralize the oxygen atoms. The exogenous antiox-
idants acting in the membrane lipids include vitamin E,
carotene, polyphenols, and flavonoids, which makes extra
virgin olive oil a natural source of such components [30].
The main role of the oil is its antioxidant function: for
this purpose, the oil should have a low peroxide content
and a high polyphenol content. Extra virgin olive oil in-
cludes 330 to 500 mg of polyphenols per kg of fat and
less than 20 milliequivalent (mEq) weight of peroxide
per kg of fat (the composition of the HOFAs includes
from 40 to 50 mg of polyphenols per kg of fat and from
230 to 340 mEq of peroxide per kg of fat). Owing to its
lipid composition, it is completely compatible with of
human tissue cells, which means that its topical use does
not cause allergy or irritation. Such properties lead us to
consider a possible protective effect on the appearance
of pressure ulcers, similar to those of HOFA, but at a
much cheaper cost, as well as offering an alternative treat-
ment option. Furthermore, there are no previous experi-
ments with this product in the prevention of pressure
ulcers in nursing care at home. The main aim of this trial
is to assess whether the effectiveness of olive oil use is
lower or higher than the HOFA in the prevention of pres-
sure ulcers in immobilized patients receiving nursing care
at home and, as a secondary aim, to assess the cost-
effectiveness of this new intervention with regard to the
use of HOFA.Methods/design
The design of this study is a noninferiority, triple-blinded,
parallel, multi-center, randomized clinical trial. The blindedgroups are the patients and their caregivers, nurses and the
research group.
The null hypothesis of this study is that the difference
in the appearance of pressure ulcers in immobilized pa-
tients at home who receive olive oil (Go), in contrast to
those patients applying HOFA (Gh) is higher than the
delta value established at 10% (H0 = Go − Gh > 10%), that
is to say, that the lower bound of the confidence intervals
includes that 10%. In the event that it is possible to reject
the null hypothesis, the alternative hypothesis of this study
will be that olive oil is not lower than 10%, compared with
the HOFA (H1 = Go − Gh < 10%); in other words, the
lower bound of the confidence interval of the difference
between both products is lower than 10%.
Two procedures will be performed: usual care and ap-
plication of HOFA to the control group and usual care
and application of an olive-oil composition to the target
group. The main outcome will be the appearance of
grade 2 pressure ulcers. The accuracy of the trial with
regard to the control medicine (HOFA) is widely sup-
ported, owing to the favorable historical results of such
medicine against placebo [25] as per recommendations
of the International Conference of Harmonization and
also because the efficiency conditions of the mentioned
medicine will be met for the purpose of this trial.
The target population will be patients included in the
immobilized-patients program within the nursing care at
home service provided in Health Centers in Andalucía
(Spain), and more specifically in the regions of Malaga,
Granada, Seville, and Cadiz.
The inclusion criteria will be: patients over 18 years;
not having pressure ulcers; patients supported by a fam-
ily or a remunerated caregiver for the application of the
treatment; diagnosed by a nurse as a ‘risk for impaired
skin integrity’, by applying the Braden Scale for prediction
of pressure ulcer risk, showing a high risk (score ≤ 12) or
moderated risk (score 13 to 16), and; patients with nutri-
tional status assessed according to the Mini Nutritional
Assessment scale scoring 10 or less.
As exclusion criteria, the following were established:
the patient declines to take part in the trial; patients with
a usual address different from the area of the health center
where the study is carried out, or plans to be away from
the usual address during the follow-up period; those pa-
tients who have been hospitalized during the sampling
period; terminally ill patients or those who already have
pressure ulcers.
All the patients included in the trial will receive the in-
formation concerning the aim of the trial in writing,
which will be duly signed by the researchers. The patients
will confirm their participation in the trial and sign an in-
formed consent form. In those cases when the patients
have cognitive impairment, the legal guardian will be the
one who signs the informed consent form. Patients who
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patients selected by the same procedure of general ran-
domized selection, thus, extending the selection process
as long as necessary.
Sample selection
The directors and care service coordinators of each health
center will be duly informed about the trial, and they will
be asked for their availability as well as their consent to
take part in the trial. Nursing staff of each health center
who so desire will be able to take part, being in such case
responsible for the research study implementation and
follow-up in their respective health center.
Records of patients included in the nursing at home
program for immobilized patients will be assessed to de-
termine whether patients comply with the inclusion re-
quirements. At this point, such patients will sign the
informed consent form and subsequently, their details will
be randomized by a computer system independent of the
professional staff, which will be processed at the clinical
trial control center.
To achieve a power rate of 80.00% to reject the null
hypothesis (H0: the difference between proportions p1
and p2 is lower than the noninferiority bound), using a
normal asymptotic analysis test (noninferiority), unilat-
eral proportions for two independent samples, taking
into account that the level of statistical significance is
5.00%, and assuming that the proportion in the reference
(control) group is 45.00% and the proportion in the ex-
perimental group is 45.00% [9], the proportion of experi-
mental units in the reference group is 50% related to
the total and the noninferiority bound (delta) is 10.00%,
then, it will be necessary to include 306 experimental
units in the reference group and 306 units in the ex-
perimental group, totalling 612 units in the study. Tak-
ing into account that the expected withdrawal rate is
15.00%, it will be necessary to enroll 360 experimental
units in the reference group and 360 units in the ex-
perimental group, totalling 720 experimental units in
the trial.
The main outcome will be the incidence of grade 2 pres-
sure ulcers in patients during the 16-weeks of follow-up
(112 days). We have selected this grade because when the
patient has grade 2 pressure ulcers, prevention can no lon-
ger be carried out, and prevention is the intended out-
come. We are only able to conduct this trial on intact
skin, therefore it is only possible to conduct the trial when
the patients have no pressure ulcer or have grade 1 pres-
sure ulcers, when there are just erythemas. Therefore, pa-
tients who develop grade 2 pressure ulcers with breaks in
the skin are excluded from the trial, as we cannot keep
using the products because prevention is not useful any-
more. Such patients will be treated again by the nurse
who will cure the pressure ulcer, although this will bedone out of the trial. When preventing the patient from
developing grade 2 pressure ulcers, we are also preventing
greater stages of ulcer. The 112 days of follow-up are
higher than trials carried out up to now, 7 days [21], 9
days [24], and 30 days [25], which is more than enough
for the appearance of pressure ulcers at any stage. The ap-
pearance of grade 2 pressure ulcers will be confirmed by
the inspection of those areas where the product has been
applied (sacrum, hips, and heels).
As secondary endpoints, cost measures will be applied
that will allow us to assess the cost-effectiveness balance
of the new product (olive-oil formula) against the HOFA-
based products. As inputs of this model, the cost of each
treatment will be used and defined as the number of
units (NEij) necessary to carry out 16 weeks’ treatment
(112 days) multiplied by the price of one unit (Pi and Pj)
(the price of each unit will be achieved from the infor-
mation provided by each supplier according to the mar-
ket price). The number of units will be the result of
dividing the treatment period (DTij) (112 days) by the
number of days (dij) the recipient used, according to the
dose established in the trial protocol in each branch of
the treatment. The resulting amount achieved shall be
rounded up, even if the whole number of units has not
been fully used:
NEij ¼ DTij=dij
As a variable cost, the number of visits of the nurse to
the patient’s home during the trial period (VEi) will be
used, which will act as a proxy measure of the level of
care required. The mean time spent on each visit will be
estimated according to the standard value of time within
the community-health nurse working hours spent during
a nursing care at home visit (this information will be
obtained from the human resources management divi-
sions of the different health districts and an assessment
test will be carried out on the length of 30 visits to patients
with the characteristics complying with the inclusion cri-
teria, randomly selected among the health centers included
in the study, prior to the commencement of the trial).
Structural fixed costs will not be included, as in all cases
the care assistance is provided at the patient’s home and
the services are already included in the aforementioned
variable. It will not be possible to assess the cost derived
from the family care, since this is quite difficult to achieve
and has a high variability. Therefore, this will not be in-
cluded in the model. In those cases when there is a remu-
nerated caregiver, such cost will not be included in the total
costs either, as it would create a bias in the estimation when
comparing them with those patients who are not assisted
by a remunerated caregiver. Furthermore, the intangible
costs derived from certain aspects, such as the pain level
derived from the process will not be included either.
Lupiáñez-Pérez et al. Trials 2013, 14:348 Page 5 of 7
http://www.trialsjournal.com/content/14/1/348Therefore, the estimation of total costs (CT) in the model
will remain as follows:
CTij ¼ NEij þ VEij:
The effectiveness variable will be the appearance of
pressure ulcers. A limited number of states will be taken
into account: appearance of pressure ulcers (U1) and
nonappearance of pressure ulcers (U0). The incidence
will be estimated in percentages, which will be used for
the incremental estimations on cost-effectiveness.
Furthermore, variables on characterization of patients
and caregivers will be included to assess sociodemogra-
phic data, such as the time registered in the care service
for immobilized patients, information about previous cases
of pressure ulcers, comorbidity, nutritional and cognitive
status, and dampness (incontinence), apart from taking
into account the ulcer location as well as the availability of
technical support items (mattress and cushions to avoid
bedsores, adjustable beds, and so on). With regard to the
caretaker, the age, sex and whether he or she is a family or
remunerated caregiver will be taken into account.
A basal-assessment will be performed on all patients
at the beginning of the trial and this will be repeated
each week up to the conclusion of the follow-up period,
or until a pressure ulcer appears in patients. All the in-
formation concerning the application of the products
will be registered in the weekly evaluations.
Procedure
The new procedure consists of the application of a for-
mula, in either liquid or spray, which contains 95% extra
virgin olive oil. This product will have the same appear-
ance as the hyperoxygenated fatty acid, using the same
presentation, which will make it appear identical to both
patients and nurses. This intervention will be applied to
both groups (control and target group). Both the pa-
tients of the control group and those patients who are
part of the target group will receive the preventative in-
structions stated in the clinical practice guidelines on
deterioration of skin integrity issued by the Health Dis-
trict of Malaga. For such purposes, the caregivers of
both groups will be trained in the mentioned proce-
dures. In addition to these preventative measures, the
patients included in the control group will receive two
applications per day of the HOFA-based product in the
skin, more specifically, in the sacral area, the hips, and
the heels. For the purpose of this trial, we will use a
HOFA product bearing the CE marking, IIb Class, with
a higher classification than other products existing in
the market. The product is to be applied topically and
includes hyperoxygenated fatty acids, Equisetum Arvense,
Hypericum Perforatum, and perfume. On their part, the tar-
get group will receive, as well as the preventative measuresmentioned above, two daily applications of the olive-oil-
based formula in the skin areas of sacrum, hips, and heels.
The appearance of pressure ulcers will be registered in the
weekly follow-up report, which will include an assessment
of whether the skin integrity is maintained or not. In the
event that there is any adverse effect during the follow-up
period, the research group will be informed and such
events will be notified by means of a specific document
designed for such purposes.
Statistical analysis
Initially, a descriptive analysis of the variables included
in the trial will be performed. Continuous variables will
be summarized with mean, standard deviation, median,
and interquartile range. Categorical variables will be shown
in absolute and relative frequencies. An analysis of the
normal distribution by the Kolmogorov-Smirnov test, sym-
metry analysis, and kurtosis will be performed.
With the aim of assessing the noninferiority of the
olive oil for the prevention of pressure ulcers, a contrast
of association between the appearance of pressure ulcers
and the kind of treatment received (olive-oil-based cream
or conventional treatment) will be carried out, by absolute
and relative measures of effect sizes (complete reduction
of risk, number needed to treat, relative risk, and relative
reduction of risk), with their respective confidence inter-
vals at 95%. It will be determined whether the confidence
interval includes the estimated delta value from the sam-
ple or not, so as to reject or accept the null hypothesis.
A bivariate analysis will be carried out using the Stu-
dent’s t and chi-squared tests according to the character-
istics of the variables analyzed in the event that these are
normally distributed. Otherwise, nonparametric tests will
be applied, such as the Wilcoxon and Man-Whitney U
tests. Likewise, analysis of variance (ANOVA) will be ap-
plied for the association of quantitative and qualitative
variables in the necessary cases, as well as robust mea-
sures of central tendency in cases of homoscedasticity
(which will be tested by Levene’s test) by means of the
Welch and Brown-Forsythe test.
An analysis according to the Kaplan-Meier curves and
log-rank test will be carried out to determine the progress
of the appearance of pressure ulcers in both groups, taking
into account the treatment applied, the sex, age, nutri-
tional status, and functional degree of the patient and the
caregiver’s age.
For the analysis on cost-effectiveness, the effectiveness
measures previously established (U1 and U0) will be ob-
tained. The increase in cost for each option (ΔCij) will be
estimated, as well as the increase of effectiveness rate,
when comparing the two options, the cost-efficiency ratio
of each treatment and the incremental cost-effectiveness
ratio of each option. These values will enable us to assess
the necessary cost to increase by 1% the possibilities of
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by using each product.
The analysis will be carried out according to the protocol,
as established for the noninferiority studies, to ensure the
difference conditions between the treatments and increase
the rejection conditions of the null hypothesis. Neverthe-
less, an analysis will be carried out that is intended to com-
pare both analyses and assess, if the analyses differ, the
subgroups of patients who did not comply with the trial
protocol with the aim of identifying the possible reasons for
the withdrawal from the trial, before accepting or rejecting
the null hypothesis. The confidence intervals of the main
result variable will be analyzed to determine whether the
difference found is within the bound established for the
delta value. Statistical analysis will be performed using SSPS
20 software.Ethical and legal issues
The Ethics and Research Committee of Malaga (Northwest
District) granted the approval for this trial. The regulations
on Good Clinical Practice will be observed at all times, as
well as the ethical principles established for the research
on human beings stipulated in the Declaration of Helsinki
and further amendments thereto. The clinical information
will remain separate from the identification details and the
databases will be coded and stored in specific computers
solely intended for the project. All the records will be made
observing all the dispositions from the legislation in force
with regard to personal data protection according to the
Act 15/1999 dated 13 December, as well as on safety of
computerized files which may store personal data infor-
mation, and more specifically, with regard to the access
through communication networks (Royal Decree 994/1999
dated 11 June) and access to confidential information for
scientific purposes from the Commission Regulation CE
No. 831/2002 by the European Union and Act 41/2002
dated 14 November, which is considered the legal standard
on Patient’s Autonomy and Rights and Duties in terms of
Clinical Information and Documentation.
The staff responsible for such purpose will manage the
data according to the instructions provided by the person
responsible for the treatment. Such data will not be applied
or used for a different purpose than those stated in the re-
spective authorization; neither will they be reproduced to
other people even for registration purposes. Once the aim
of the trial has been carried out, the personal data collected
will be destroyed, deleted, or given back to the person re-
sponsible for the treatment, along with any other media or
documents containing any personal data related to the
project. Every patient will be informed verbally and in
writing about the objectives of the project and its meth-
odology. Each individual will sign the respective in-
formed consent form.Discussion
Pressure ulcers are nowadays considered an important
health issue causing a great economic impact by substan-
tially increasing pharmaceutical expenditure. The total ex-
penditure of pressure ulcer treatments amounts to 5% of
annual health care expenditure and causes a higher health
care burden on professional staff. This is a public health
problem, which affects mainly older people, thus, this dis-
ease rate is increasing.
The acceptance of our hypothesis will provide evidence
supporting the regular use of olive oil (nonoxygenated
fatty acids) in the prevention of pressure ulcers in primary
health care, likewise involving hospital care. Furthermore,
owing to the lower price of the product, primary health
care districts may consider purchasing them, owing to the
reduction in health care workload for professional staff, as
well as for the family caregivers, given that the incidence
of pressure ulcers will be lower as well as the respective
reduction in pharmaceutical expenditure.
The main limitation of the trial is that when performing
the cost-effectiveness analysis, the variables on caregiver
inputs may not be estimated, along with those variables
regarding the expenditure derived from the patient’s suf-
fering. Likewise, there might be a selection bias due to
those patients who refuse to take part in the trial, which
may involve differential baseline characteristics. For the
purposes of this trial, in the analysis it will be taken into
account whether there are differences among those who
take part in the trial and those who do not. The same pro-
cedure will be applied for withdrawals during the follow-
up period. The analysis will be carried out according to
the protocol and intention to treat. In the event that the
results of the two types of analysis do not match, the sub-
group of patients who did not comply with the protocol
will be studied, to determine the reasons before reaching a
final conclusion of noninferiority.
The confusion bias derived from some variables such
as age, sex, type of intervention, and nutritional status of
the patient will be managed during the statistical analysis
stage, by means of a multivariate analysis.
The usual application of olive-oil-based formulas may
be helpful in preventing the appearance of any grade of
pressure ulcer in immobilized patients, and thus, it will
be a cheaper treatment and may be considered as an al-
ternative treatment.
Trial status
The randomized trial is currently in the phase of pa-
tient’s enrolment and follow-up.
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